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standard treatment for this age group. Several recent studies suggest 
superiority of combination CT, but little is known about QoL during 
CT. Also better assessments are needed to select elderly pts suitable for 
combination CT. The aim of this study was to investigate the effect of 
both platinum-based regimens on changes in QoL and the tolerability 
of these treatments in elderly NSCLC pts.
Methods: Eligible were pts ≥ 70 years with advanced NSCLC. They 
received carboplatin (AUC 5 day 1)-gemcitabine (1250 mg/m2 days 1 
and 8) or carboplatin (AUC 5 day 1)-paclitaxel (175 mg/m2 day 1), q 
3 weeks, for a maximum of 4 cycles. Darbepoetin was started if Hb < 
11 g/dL. Primary endpoint was the change in global QoL from baseline 
compared with week 18, using the EORTC QLQ-C30. Among the sec-
ondary endpoints were toxicity, response rate and survival. In addition, 
the value of a comprehensive geriatric assessment (CGA) was used.
Results: 182 pts were randomized. At the time of this analysis informa-
tion was available on 168 pts. Mean age was 75 yrs (range 70-85). PS 
= 0 in 30%, 1 in 57% and 2 in 13%. 64% of pts completed all 4 cycles, 
10% stopped treatment prematurely due to toxicity, 13% due to PD. 
Toxicity related dose-reductions occurred in 28 and 8% of pts and 
dose-delays in 15 and 3% of pts in the CG and CP arm, respectively. 
Overall, grade III/IV toxicity occurred in 65% of pts (75% in CG arm, 
56% in CP arm), toxicity related SAEs in 17% (20% in CG arm, 15% 
in CP arm), and 36% experienced ≥ grade 2 neurological toxicity (30% 
CG arm, 43% CP arm). Response rates were 28% in the CG arm vs 
20% in the CP arm. Median survival and progression-free survival were 
7.7 and 4.7 months for the CG arm and 6.6 and 4.4 months for the CP 
arm, respectively. 56 % of pts in the CG arm and 49% in the CP arm 
completed both the QoL questionnaires at baseline and after 18 weeks. 
Mean global QoL score at baseline did not differ between both arms 
(66% for GC and CP). After 18 weeks the mean QoL score for the CG 
arm had decreased by 2% and for the CP arm by 8% (NS). Further-
more, changes in Qol scores over the period of 18 weeks did not differ 
signiﬁcantly between both treatment arms. For experiencing grade 
III/IV toxicity related SAEs, neurological toxicities and for ﬁnishing all 
cycles, the use of a CGA was of predictive value.
Conclusions: In elderly patients with advanced NSCLC differences in 
treatment-related toxicity from gemcitabine and paclitaxel administered 
with carboplatin have no differential inﬂuence on QoL. Response and 
survival rates are similar for both groups. 
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Background: The combination of docetaxel and cisplatin is an ef-
fective ﬁrst-line chemotherapy for advanced NSCLC. However, the 
recommended three-weekly schedule is frequently associated with 
neutropenia and neutropenic infections. Moreover, the relatively long 
hydration required with cisplatin given every three weeks makes outpa-
tient treatment more difﬁcult. We assessed the efﬁcacy and tolerability 
of weekly docetaxel-cisplatin, which may be better tolerated than the 
standard regimen.
Methods: Patients (pts) with histologically conﬁrmed stage UICC IIIB 
(malignant effusion) or IV NSCLC received docetaxel (35 mg/m2, 30 
min. infusion) and cisplatin (25 mg/m2, 30-min. infusion) on days 1, 8, 
and 15, every 4 weeks for 4-6 cycles. Pts received ondansetron 8 mg iv 
and dexamethasone 8 mg iv preceding every day of chemotherapy and 
oral dexamethasone 2 x 4 mg daily from the day before until the day 
after chemotherapy. NK1-antagonists were given at the investigator’s 
discretion. Most pts were treated in an outpatient department. Safety 
was assessed using CTCAE v3.0. The primary endpoint was response 
rate (RECIST).
Results: 45 pts were included; efﬁcacy and tolerability data were avail-
able for 43 pts. 12/45 pts achieved an objective response (11 partial; 
1 complete; ITT response rate 27%). Median time to progression was 
3.9 months. Pts received a median of 3 full cycles. 4 pts (9%) required 
dose reductions. No cases of neutropenic fever/infections or grade 2-4 
thrombocytopenia were observed. One pt (2%) experienced grade 3/4 
nausea/vomiting. 5 pts died during therapy for reasons not unequivo-
cally attributable to tumor progression (bacterial meningitis with nor-
mal neutrophil counts [n=1], pneumonia with normal neutrophil counts 
[n=1], pulmonary arterial embolism [n=1], unknown [n=2]).
Conclusions: Weekly docetaxel-cisplatin was well tolerated. The 
schedule can be safely administered with relatively low hydration vol-
umes in an outpatient setting. Survival data will be presented.
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Metastatic NSCLC clinical trials evaluating the role of palliative che-
motherapy often underrepresent or exclude patients with brain metas-
tases. The prognosis for this subgroup of patients remains poor and the 
advantage of chemotherapy, after deﬁnitive whole brain radiotherapy 
(WBRT), remains unclear. A retrospective chart review of NSCLC pa-
tients presenting with synchronous brain metastases in Alberta, Canada 
from 2000-2004 was undertaken to examine the possible beneﬁts of 
chemotherapy following WBRT. 497 chemonaive NSCLC patients with 
brain metastases received brain radiotherapy from 2000-2004, but only 
30 patients (6%) received subsequent chemotherapy. Of the 30 patients, 
the median age was 54 years (range 29 to 69 years), 40% were male, 
87% had an ECOG performance status ≤ 2 and 60% had adenocarci-
noma subtype of NSCLC. The treatment of the brain metastases, prior 
to chemotherapy, consisted primarily of WBRT (62% of patients irradi-
ated with 30 Gy in 10 fractions; 38% patients irradiated with 20 Gy in 
5 fractions), whereas only one patient underwent stereotactic radiosur-
gery. An intracranial response or stable disease was observed in 66% 
of patients. When treated with chemotherapy after brain radiotherapy, 
97% received a platinum-based doublet for a median of 4 cycles (range 
1-6). The response rate to ﬁrst-line chemotherapy was 30%, and 10 
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patients (33%) had second-line chemotherapy (the majority received 
docetaxel) after progression. The median overall survival was 11.0 
months (95% CI=7.4, 14.6) in those patients who received chemother-
apy after brain radiotherapy. Our results show that only a small fraction 
of NSCLC patients presenting with synchronous brain metastases are 
even considered for chemotherapy after WBRT. Although limited by 
the retrospective nature of the study, good performance status (ECOG 
0-2) NSCLC patients with brain metastases who receive chemotherapy 
after brain radiotherapy have response rates and a median survival 
comparable to the general Stage IV NSCLC population. We propose 
that chemonaive NSCLC patients who receive radiotherapy treatment 
for synchronous brain metastases, and maintain an adequate perfor-
mance status, should be considered for chemotherapy and should not be 
routinely excluded from clinical trials involving systemic therapy.
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Background: The combination of cisplatin and vinorelbine is a refer-
ence regimen in ﬁrst-line therapy for advanced NSCLC. The correla-
tion between predictive genetic markers and clinical endpoints may 
improve the prediction of treatment success and thereby the tailoring 
of chemotherapy. In this trial, predictive genetic markers of response to 
CDDP/VRL were examined in genomic DNA and cDNA derived from 
tumors and circulating tumors. 
Methods: 238 chemonaive p with stage IIIB (pleural effusion or 
supraclavicular lymph nodes)-IV or recurrent NSCLC were accrued at 
35 sites between April 2004 and January 2006. Treatment consisted of 
CDDP 75 mg/m2 IV day 1 plus VRL 25 mg/m2 IV or 60-80 mg/m2 oral, 
days 1, 8 every 21 days. DNA samples were collected from primary 
tumors for the assessment of microtubule associated protein 4 (MAP4) 
and from serum for checkpoint forkhead-associated and ring ﬁnger 
(CHFR) methylation. 
Results: Data on 207 p is available. Median age 62 years (38-80); 
males: 84.5%; smokers: 79.2%; PS 0-1: 94.5%; adenocarcinoma, 
48.4% / squamous, 34.2%; stage IIIB: 16.9%, IV: 83.1%. Median 
cycles: 4 (1-12). Hematological toxicities (%p): grade 3/4 neutropenia, 
8.7%/7.7%; grade 3/4 thrombocytopenia, 0.5%/1.0%; grade 3 anemia, 
2.4%. Febrile neutropenia appeared in 12 p (5,3%). Non-hematologi-
cal toxicities (%p): pulmonary grade 3/4, 3.4%/2.4%; nausea/vomiting 
grade 3/4, 7.7%/0.5%; asthenia grade 3, 12.6%; pain grade 3, 5.8%; 
infection grade 3/4, 3.9%/0.5%; neurotoxicity grade 3, 0.5%. Efﬁcacy 
in evaluable population: CR, 2.8%; PR, 30.7%; ORR, 33.5% (95% 
CI, 26.6% to 40.4%); SD, 36.3%. With a median follow up of 6.6 
months, median survival for the whole population was 8.9 months (m), 
progression free survival 5 m, event free survival 4.8 m, 1-year survival 
39.4%.
Conclusions: The tolerability, efﬁcacy and survival results of this trial 
conﬁrm that CDDP/VRL is effective as ﬁrst-line therapy, presenting a 
favourable toxicity proﬁle in p with advanced NSCLC. Complete data 
on genetic markers will be presented.
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Aim: This Phase II study was conducted in order to deﬁne the efﬁcacy 
and safety of Carboplatin-Pemetrexed combination as a second-line 
treatment for NSCLC patients.
Patient and Methods: Twenty six patients with measurable NSCLC 
and PS 0-1 (ECOG scale) who had failed or relapsed after initial 
chemotherapy, received Carboplatin AUC4 and Pemetrexed 350mg/m2 
on day 1 and 15 on up to 6 q28 cycles. Vitamin B12 and folic acid 
supplementation was given. All patients received GCSF for days 3-5 
and 17-19 of cycles. Response to treatment was evaluated by response 
evaluation criteria in solid tumors (RECIST), and toxicity was graded 
according to the National Cancer Institute Common Toxicity Criteria 
version 3.0.
Results: The most common severs hematological adverse events (CTC 
Grade 3,4) was thrombocytopenia in two patients (7.6%), and anemia 
in one (3.85%). Serious non hematological toxicity was onycholyses 
(3.85%), neuropathy (3.85%), stomatitis (3.85%), and fatigue (3.85%). 
The median number of treatment cycles was 4. Fourteen patients (54%) 
received all six cycles. One patient reported as complete responder 
(3.85%), 5 as partial responders (19%) and 4 had stable disease 
(15.4%), with over all response rate of 38.46%. Median time to pro-
gression for 2nd line chemotherapy and overall survival was 6 and 12.6 
months respectively. 
Conclusions: Second line regimen with carboplatin-pemetrexated in 
intensive schedule is well tolerate and effective treatment for resistant 
or relapsed, after initial chemotherapy, NSCLC.
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Objective: To study the effects of Taxotere, Celecoxib and the combi-
nation of both on proliferation and apoptosis of NSCLC cell. 
Methods: Investigate the effect of Taxotere, Celecoxib and the combi-
nation of both on proliferation of NSCLC A549 by MTT assays. Detect 
the change of apoptosis, cell cycle and the expression of COX-2 protein 
using ﬂow cytometry analysis and immunocytochemistry, respectively. 
